Source comparison
Hexarelin vs Ipamorelin — Research Peptide Comparison
The GHRP (growth hormone-releasing peptide) family contains dozens of synthetic analogues, yet fewer than 20% demonstrate the receptor selectivity required for controlled research applications. Hexarelin and ipamorelin both stimulate growth hormone release thr
This comparison does not assign a generated winner or score.
- The GHRP (growth hormone-releasing peptide) family contains dozens of synthetic analogues, yet fewer than 20% demonstrate the receptor selectivity required for controlled research applications. Hexarelin and ipamorelin both stimulate growth hormone release through ghrelin receptor agonism, but their structural differences produce dramatically different side effect profiles—differences that matter when research protocols demand consistency across multi-week trials.
- We've worked with research teams across metabolic studies, tissue repair models, and aging research for years. The single most common peptide selection mistake isn't about dosing or reconstitution—it's choosing a compound based on GH output alone without accounting for off-target receptor activity that introduces confounding variables into every data point collected.
- What is the difference between hexarelin and ipamorelin?
- Hexarelin is a first-generation GHRP with potent growth hormone-releasing activity but significant cortisol and prolactin elevation due to broad ghrelin receptor binding. Ipamorelin is a third-generation selective GHSR-1a agonist that stimulates GH release without measurable cortisol or prolactin increases, making it the preferred choice for research requiring hormonal stability. The mechanistic difference—receptor selectivity—determines which peptide produces cleaner data in controlled studies.
- Yes, both peptides increase growth hormone secretion through ghrelin receptor pathways, but that's where the functional similarity ends. Hexarelin binds to multiple ghrelin receptor subtypes (GHSR-1a, GHSR-1b, and CD36 scavenger receptors), triggering a cascade that includes cortisol release from the adrenal cortex and prolactin secretion from lactotroph cells. Ipamorelin's tighter binding specificity limits activity almost exclusively to GHSR-1a receptors in the pituitary, producing GH pulses that mirror endogenous secretion patterns without the hormonal disruption. This article covers the exact receptor mechanisms that differentiate these compounds, the quantitative side effect differences documented in peer-reviewed studies, and how to match peptide selection to specific research objectives where hormonal stability matters.